The present disclosure refers to a method for the measurement, diagnosis, treatment, and management of metabolic syndrome comprising the administration of a drug for the treatment of metabolic syndrome and a system for monitoring a drug product to a patient in need thereof, to prevent or reduce the risk of metabolic syndrome and related disorders, by using electronic devices.

The present invention relates to a human AMHRII-binding agent for its use for preventing or treating a cancer selected in a group of cancers comprising colon cancer, liver cancer, hepatocellular carcinoma, testis cancer, thyroid cancer, gastric cancer, gastrointestinal cancer, bladder cancer, pancreatic cancer, head and neck cancer, kidney cancer, liposarcoma, pleuramesothelioma, melanoma, sarcoma, brain cancer, osteocarcinoma and leukemia.

Provided herein are methods for detecting an antigen or for detecting expression of a chimeric antigen receptor (CAR). The methods include obtaining a sample from a subject, contacting the sample with a fusion protein comprising a reporter fused to a single chain antibody specific to the antigen or fused to an extracellular domain of an antigen targeted by the CAR or fused to Protein L and assaying the activity of the reporter, wherein presence of reporter activity or increase in reporter activity relative to a reference value is indicative of presence of the antigen or presence of the expression of the chimeric antigen receptor in the sample.

The present invention is relevant to polypeptides and novel methods of polypeptide evolution. The present invention further relates to methods of identifying a cross-species mutant polypeptide from, or based upon, a template polypeptide.

Biomarkers useful for diagnosing and assessing inflammatory disease are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. The biomarkers include at least two biomarkers selected from the DAIMRK group and the score is a disease activity index (DAI).

The present invention is relevant to polypeptides and novel methods of polypeptide evolution. The present invention further relates to methods of identifying a cross-species mutant polypeptide from, or based upon, a template polypeptide.

This disclosure provides a method for polymerizing polyphenols to provide polyphenol polymers using peroxidase and similar catalysis. In various aspects, it provides a method for polymerizing a polyphenol (e.g., polydopamine or a derivative or conjugate thereof) on a surface comprising polymerizing the polyphenol, a method for detecting an analyte comprising polymerizing a polyphenol, and an assay kit comprising a polyphenol (e.g., dopamine or a dopamine derivative). In one embodiment, a method for polymerizing a polyphenol includes contacting the polyphenol and an oxidant with an enzyme having peroxidase-like activity, under conditions sufficient to polymerize the polyphenol. In another embodiment, a method for depositing a polyphenol polymer (e.g., a polydopamine) includes providing, at a target site, an enzyme having peroxidase-like activity immobilized at the surface; and polymerizing, at the target site, a polyphenol in the presence of an oxidant and the enzyme to provide the polyphenol polymer, deposited on the surface.

Methods for determining the presence of pathologic amylin in a subject with diabetes or pre-diabetes are provided herein. The method includes obtaining a skin sample from a subject and determining if there is pathologic amylin present in the skin sample.

A system includes a fluid transfer device and a lateral flow assay device. The fluid transfer device has an inlet fluidically coupleable to a bodily fluid source, an outlet fluidically coupleable to a sample reservoir, and a sequestration chamber configured to receive an initial volume of bodily fluid. The fluid transfer device can be transitioned between (1) a first state with the sequestration chamber in fluid communication with the inlet to receive the initial volume, (2) a second state with the outlet in fluid communication with the inlet to receive a subsequent flow of bodily fluid, and (3) a third state with the lateral flow assay device in fluid communication with the sequestration chamber to receive a portion of the initial volume of bodily fluid. The lateral flow assay device configured to provide an indication associated with a presence of a target analyte in the bodily fluid.

The present invention relates to a method of determining the gestational diabetic status of a pregnant subject, comprising providing a biological sample obtained from the subject; and determining the presence, and/or level, of syncytiotrophoblast extracellular vesicles, and/or insulin receptor, and/or DPPIV in the biological sample.